SLC25A3

Solute carrier family 25 member 3 · Q00325 · SLC25A3 on Sugi Atlas →

0 patent compounds predicted against SLC25A3, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SLC25A3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation PHASE2/PHASE3UNKNOWN
Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorder PHASE1/PHASE2NOT_YET_RECRUITING
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia PHASE1/PHASE2COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime PHASE1COMPLETED
Tolerability of Enteral NAC in Infants PHASE1NOT_YET_RECRUITING
Multi-omics Study in Citrin Deficiency nanACTIVE_NOT_RECRUITING
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
SLC13A5 Deficiency Natural History Study - United States Only nanENROLLING_BY_INVITATION
Expression of SLC25A48 in Chronic Obstructive Pulmonary Disease nanNOT_YET_RECRUITING
Oxalate and Citrate in Humans - Response to Citrate nanRECRUITING
Genetic Variations That Increase the Risk for Calcium Kidney Stones: a Family-based Study nanCOMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts nanCOMPLETED
Effect of SLC01B1 (rs2306283) Polymorphism on the Efficacy and Safety Profile of Atorvastatin in Pakistani Population nanCOMPLETED
SLC13A5 Deficiency Natural History Study - Remote Only nanENROLLING_BY_INVITATION
Bile Acid Effects in Fetal Arrhythmia Study nanUNKNOWN
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides nanCOMPLETED
Gastrostomy-Biliary Diversion: Innovative Management for Bile Canalicular Transport Disorders nanUNKNOWN
Oxalate and Citrate nanRECRUITING
Role of the ATP7A Transporter in Ovarian Cancer nanCOMPLETED
Triheptanoin (UX007) to Treat Citrate Transporter Deficiency nanNO_LONGER_AVAILABLE
Identification of New Candidate Genes in Patients With Mitochondrial Disease by High Resolution Chromosome Analysis on DNA Chip nanCOMPLETED
Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes nanRECRUITING
Identification and Characterization of Monogenic Diabetes nanCOMPLETED
Genotype-phenotype Correlation of SLC26A4 in CI Patients With EVA nanUNKNOWN
Epidemiology of Gout in French Polynesia nanCOMPLETED
Hyperlactacidemia in Major Abdominal Surgery and Monocarboxylate Receptors nanUNKNOWN
Survey on Supplement Use in Mitochondrial Disease nanCOMPLETED
Molecular Epidemiology of Parkinson's Disease nanCOMPLETED
Pediatric Evaluation and Registry for Liver Cholestasis in Canada nanRECRUITING
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC25A3 binder may also engage these)

ProteinNameSimilarity
Q5R7W2 1.000 Q5R7W2 →
P16036 0.999 P16036 →
P12234 0.999 P12234 →
Q8VEM8 0.998 Q8VEM8 →
Q9FMU6 0.990 Q9FMU6 →
O61703 0.988 O61703 →
P40614 0.985 P40614 →
Q9M2Z8 0.984 Q9M2Z8 →
O49447 0.981 O49447 →
O22342 0.976 O22342 →
P04709 0.976 P04709 →
P12857 0.973 P12857 →
P25083 0.972 P25083 →
P31691 0.971 P31691 →
P40941 0.971 P40941 →
Q7DNC3 0.969 Q7DNC3 →
P27081 0.967 P27081 →
P31167 0.967 P31167 →
Q9P7V8 0.966 Q9P7V8 →
P23641 0.966 P23641 →
Q41630 0.966 Q41630 →
P31692 0.964 P31692 →
Q09188 0.962 Q09188 →
Q9VQ37 0.961 Q9VQ37 →
Q9FLS8 0.960 Q9FLS8 →
G3YC86 0.960 G3YC86 →
P18239 0.960 P18239 →
O13844 0.958 O13844 →
P40035 0.958 P40035 →
Q58DS3 0.958 Q58DS3 →